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E-mail address: g.sapkota@dundee.ac.uk (G.P. SapkSMAD transcription factors are key mediators of the transforming growth factor-beta (TGFß) family
of cytokines. Reversible phosphorylation of SMAD proteins plays a key role in regulating their
function. Several phosphatases have been proposed to act on SMAD proteins to inﬂuence TGFß/
BMP signalling. Here we provide an overview of the SMAD regulation by different protein phospha-
tases and review the evidence supporting each phosphatase as a candidate SMAD-phosphatase.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V.1. Introduction to the TGFß signalling
The signalling pathways downstream of the transforming
growth factor beta (TGFß) family of cytokines, including bone mor-
phogenetic proteins (BMPs), are critical during development and in
adult tissue homeostasis [1–3]. They control plethora of cellular
processes including proliferation, differentiation, extra-cellular
matrix production, motility, survival and fate [1,2]. When compo-
nents of the TGFß pathway are compromised, numerous human
diseases, including ﬁbrosis, cancer progression and metastasis, re-
sult [4–7]. For this reason, complex biochemical mechanisms have
evolved to intricately control the extent, duration and potency of
signalling downstream of the TGFß ligands. TGFß ligands initiate
signalling by binding to a pair of cell-surface receptor serine thre-
onine protein kinases (termed type II and type I). Upon ligand
binding the type II receptors form heterotetrameric complexes
with speciﬁc type I receptors, which in turn phosphorylate and
activate SMAD transcription factors (often termed receptor regu-
lated SMADs or R-SMADs) [8–10]. The phosphorylation of R-
SMADs triggers their association with SMAD4 and translocation
to the nucleus, where they control the transcription of hundreds
of TGFß/BMP-target genes [2]. The TGFß family of ligands can
broadly be divided into two groups based on their ability to prefer-
entially trigger the activation of speciﬁc SMAD transcription fac-
tors. The TGFß subfamily (including TGFß, Activin and Nodal)al Societies. Published by Elsevier
ota).activates SMADs 2 and 3, while the BMP subfamily (including
BMPs, GDFs and AMH) activates SMADs 1, 5 and 8 [2]. The TGFß
subfamily of ligands signals through speciﬁc type II (TGFßR-II or
ActR-IIB) and type I (ALK4, ALK5 or ALK7) receptors while the
BMP subfamily of ligands employs selective type II (BMPR-II or
ActR-IIA/B or AMHR-II) and type I (ALK1, ALK2, ALK3 or ALK6)
receptors [2].
2. R-SMADs: the key mediators of the TGFß signals
SMAD transcription factors are highly conserved from
Drosophila to mammals. Three distinct structural features deﬁne
R-SMADs: the highly conserved Mad Homology 1 (MH1) domain
at the N-terminus and the Mad Homology 2 (MH2) domain at
the C-terminus linked by a divergent linker region (Fig. 1). The
MH1 domain exhibits sequence-speciﬁc DNA binding activity and
negatively regulates the function of MH2 domain [1,2]. The MH2
domain is responsible for receptor interaction, formation of heter-
omeric SMAD complexes as well as interaction with DNA binding
partners and transcription factors. The phosphorylation of the
two C-terminal Ser residues in the Ser-Xaa-Ser motif of the MH2
domain drives the activation of R-SMADs [1,2]. The divergent lin-
ker region contains several Ser/Thr residues that are phosphory-
lated by various kinases in response to different stimuli (Fig. 1).
Additionally there is a PPXY motif that mediates interaction with
selective WW-domain containing E3 ubiquitin ligases (Fig. 1).
R-SMADs are indispensable for mediating the cellular responses
to TGFß/BMP signals. Consequently, R-SMADs are key targets forB.V. Open access under CC BY-NC-ND license.
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Fig. 1. R-SMADs are phosphorylated at multiple residues. (A) Representation of the reported and novel phospho-residues within the MH1, linker or MH2 domains of human
SMAD1. The kinases and agonists mediating the phosphorylation of individual sites are also indicated. Conserved residues in SMAD5 and 8 are phosphorylated at the
equivalent sites. (B) Representation of the reported and novel phospho-residues within the MH1, Linker or MH2 domains of human SMAD3 (SMAD2 sites are indicated with
asterisks). The kinases and agonists mediating the phosphorylation of individual sites are also indicated. Conserved residues in SMAD2 are also phosphorylated at the
equivalent sites. The PPXY (PY) motif in the linker region mediates interaction with the WW-domain containing proteins.
1898 D.L. Bruce, G.P. Sapkota / FEBS Letters 586 (2012) 1897–1905regulatory inputs from various proteins and downstream of other
signalling networks that modulate the outcome of TGFß/BMP sig-
nals. Various post-translational modiﬁcations of R-SMADs have
been reported to affect their activity, stability and localisation in
cells [11,12]. Reversible phosphorylation of R-SMADs, mediated
by protein kinases and phosphatases, is crucial in regulating the
precise nature of cellular responses to TGFß/BMP ligands. The
mechanisms by which phosphorylation of R-SMADs regulates their
activity, localisation and stability are generally well established
[11,12]. However our understanding of the mechanisms by which
different phosphatases regulate R-SMADs is still emerging. Despite
numerous R-SMAD phosphatases proposed to impact TGFß/BMP
signalling, the ﬁeld still remains largely sceptical on their roles.
This review focuses on all the proposed R-SMAD phosphatases
and discusses the further evidence needed for each phosphatase
to establish it as a convincing candidate.3. Phosphorylation of R-SMADs is key to their function
R-SMADs are directly phosphorylated at multiple Ser/Thr resi-
dues in response to different agonists by distinct protein kinases
(Fig. 1A and B). Two R-SMAD phosphorylation events are best char-
acterized: (a) the phosphorylation of C-terminal SXS motif (termed
tail-phosphorylation) by the type I receptor kinases and (b) the
phosphorylation of multiple Ser/Thr residues in the linker-region
(termed linker-phosphorylation) by various proline-directed ki-
nases. Most proposed R-SMAD phosphatases to date have only ad-
dressed the dephosphorylation of these events. However, it is
noteworthy that there are additional Ser/Thr residues within
R-SMADs that are also phosphorylated by different kinases in
response to different agonists (Fig. 1A and B). Any R-SMAD-
associating phosphatase could potentially also act as a R-SMADphosphatase against any number of these phosphorylation sites.
Below we discuss the phospho-regulation of R-SMADs.
3.1. R-SMAD tail phosphorylation
Upon formation of the ligand-receptor complexes, the constitu-
tively active type II receptor kinases phosphorylate the ‘GS’ domain
of the type I receptor kinases, which activates them [10,13] (Figs. 2
and 3). The activated type I receptors in turn bind to the R-SMADs
through their MH2 domains and rapidly phosphorylate the dual
Ser residues in the C-terminal Ser-Xaa-Ser motif of R-SMADs
[14,15]. In the BMP pathway, activated ALKs1, 2, 3 or 6 can phos-
phorylate SMAD1 at Ser463 and Ser465 and corresponding resi-
dues on SMADs 5 and 8. In the TGFß pathway, activated ALKs 4,
5 or 7 phosphorylate SMAD2 and SMAD3 at Ser465/Ser467 and
Ser423/Ser425, respectively [1,2]. Phosphorylation of R-SMADs at
the tail triggers association with SMAD4 and nuclear translocation
[16,17]. SMAD4 lacks the critical SXS motif but is essential and
non-redundant in mediating TGFß/BMP signals. The phosphoryla-
tion of SXS motif in SMADs is indispensable for cellular responses
to TGFß/BMP ligands [1,2]. Indeed mouse embryos in which endog-
enous SMAD1 gene is replaced with SMAD1(SVS-AVA) mutant dis-
play many of the SMAD1-null phenotypes [18].
3.2. R-SMAD linker phosphorylation
The linker region of R-SMADs is divergent in that the sequence
similarity in this region between the TGFß SMADs (2 & 3) and the
BMP SMADs (1, 5 & 8) is low. However within each subfamily there
is a high degree of sequence similarity. The linker region of all R-
SMADs has two key features: the presence of a PPXY motif and
the abundance of proline-directed Ser/Thr residues. The PPXY
motif is known to interact with selective WW-domain containing
Fig. 2. Phosphatases regulating the TGFß pathway. The phosphatases reported to impact the TGFß signalling and their predicted sites of action are indicated. As discussed in
the text, the subcellular localisation of PPM1A is still disputed.
Fig. 3. Phosphatases regulating the BMP pathway. The phosphatases reported to impact the BMP signalling and their predicted sites of action are indicated.
D.L. Bruce, G.P. Sapkota / FEBS Letters 586 (2012) 1897–1905 1899proteins [19–23], while the proline-directed Ser/Thr residues can
be phosphorylated by any number of proline-directed protein ki-
nases (Fig. 1). Several MAPKs downstream of mitogens, growth fac-
tors and stress induce the phosphorylation of several proline-
directed Ser/Thr residues in R-SMADs, including Ser187, Ser195,
Ser206, Ser214 and Thr222 in SMAD1 and Thr179, Ser204,
Ser208 and Ser213 in SMAD3 [20,21,24–28] (Fig. 1A and B). Addi-tionally, GSK-3 can phosphorylate Ser210, Thr202, Ser198 and
Ser191 in SMAD1 following priming phosphorylation at Ser214,
Ser206 and Ser195 [21]. Interestingly, TGFß and BMP ligands
themselves induce the phosphorylation of the same proline-direc-
ted Ser/Thr residues in the linker region of the respective R-SMADs
(Fig. 1A and B) [21,25]. The ligand-induced phosphorylation of the
linker region follows tail-phosphorylation and is mediated by
1900 D.L. Bruce, G.P. Sapkota / FEBS Letters 586 (2012) 1897–1905nuclear kinases, CDK8 and CDK9 [24]. The phosphorylation of the
linker region of SMADs modulates the R-SMAD function by affect-
ing their localisation, transcriptional ability and turnover
[20,21,24–28]. Phosphorylation of SMAD1 at the linker region by
proline-directed kinases and GSK-3 primes SMAD1 for recognition
and polyubiquitylation by SMURF1 [21,25]. Similarly SMAD3 linker
phosphorylation triggers its recognition and polyubiquitylation by
NEDD4L [20]. Conversely the ligand-induced linker phosphoryla-
tion mediated by CDK8/9 can promote SMAD transcriptional action
prior to turnover [24]. An effector of the Hippo signalling pathway,
YAP, which is required for the BMP-dependent suppression of neu-
ral differentiation of mouse embryonic stem cells, is recruited by
linker phosphorylated SMAD1 [24]. Additionally CDK2/4 have been
reported to mediate the phosphorylation of Thr179 and Ser213 of
SMAD3 leading to inhibition of TGFß-transcriptional activity [28].
3.3. Other phosphorylation sites in R-SMADs
In addition to the tail- and linker-phosphorylation sites dis-
cussed above, several other phospho-sites in R-SMADs have been
reported (Fig. 1A and B). A Ste20 kinase Misshapen (a MINK1
ortholog) was shown to inactivate Mad by phosphorylating it at
Thr312 (equivalent to Thr322 in SMAD1) [29]. Furthermore, we
have identiﬁed a novel phospho-Ser132 peptide by mass-spec-
trometry from SMAD1-immunoprecipitates, although kinase(s)
mediating this phosphorylation and its role are unclear (data not
shown) (Fig. 1A). CamKII has been reported to phosphorylate
SMAD2 at Ser110, Ser240 and Ser260 leading to inhibition of the
TGFß pathway [30]. WNK1/4 have been reported modulate SMAD2
levels and localisation by phosphorylating SMAD2 at Ser110,
Ser260 and Ser423 [31]. PKC was shown to inhibit TGFß signalling
by phosphorylating SMAD3 at Ser37 and Ser70 [32]. Similarly, PKG
has been reported to inhibit SMAD3 nuclear localisation by phos-
phorylating SMAD3 at Ser309 and Thr368 in the MH2 domain
[33]. SMAD3 stability is reportedly controlled in part by phosphor-
ylation of at Thr66 by GSK-3 [34] and at Ser418 by CSNK1G2 [35].
Furthermore, we have identiﬁed a novel phospho-Thr132 peptide
from SMAD3-immunoprecipitates (data not shown). The above
studies clearly demonstrate that R-SMADs are regulated by phos-
phorylation at multiple residues, on which a phosphatase could
potentially act to reverse the phosphorylation.
4. Protein phosphatases reverse the action of protein kinases
Given that intracellular signalling by R-SMADs is reliant on their
phosphorylation by different protein kinases under different bio-
logical contexts, removal of phosphates from phospho-residues cat-
alysed by protein phosphatases is the most effective way of
reversing the phospho-dependent R-SMAD signalling and restoring
the R-SMAD to baseline. Dephosphorylation of proteins by protein
phosphatases is a fundamental regulatory mechanism in control-
ling the activity of many proteins in signal transduction. While
the protein kinase family is one of the largest enzyme groups en-
coded by the human genome (518 genes), there are relatively few-
er protein phosphatases encoded (147 phosphatases) [36,37].
Protein phosphatases are therefore far more promiscuous with re-
gards to their substrate speciﬁcity compared to protein kinases,
which display a high degree of substrate speciﬁcity. Phosphatases
are classiﬁed according to their substrate preference: 38 are protein
tyrosine phosphatases (PTPs), 40 are serine-threonine phospha-
tases (S/TPs) and the remainder (DUSPs) display dual (Ser/Thr-
Tyr) substrate-speciﬁcity. All reported phosphorylation sites in
R-SMADs are on Ser/Thr residues. Therefore S/TPs have been the
major focus for research on SMAD phosphatases. S/TPs are further
classiﬁed into three groups based on the amino acid sequence com-position and structure of the catalytic domain: the PPP (Phospho-
Protein Phosphatase) family, of which PP1 is the prototypic mem-
ber; the PPM (protein phosphatase, Mg2+/Mn2+-dependent) family,
of which PPM1A/PP2C is the prototypic member; and FCP (tran-
scription factor IIF-interacting CTD phosphatase 1) family, of which
FCP is the founding member. The PPP and PPM family display little
amino acid sequence similarity surrounding the active sites but the
three-dimensional structures of the catalytic subunits are similar
[38]. The PPP subfamily often requires one or more regulatory sub-
units for catalysis and is robustly inhibited by okadaic acid [38]. The
PPM family of phosphatases aremonomeric and generally consist of
a catalytic domain that is ﬂanked by short N- and C-terminal se-
quences. The FCP family, which includes Small C-terminal domain
Ser/Thr phosphatases (SCPs), possesses a distinct amino acid con-
sensus sequence and catalytic mechanism [38].
5. Role for R-SMAD phosphatases in TGFß/BMP signalling
Evidence for the role and nature of potential R-SMAD phospha-
tases has been highlighted by many early observations, primarily
on the dynamics and kinetics of tail-phosphorylated R-SMADs in
cells. Early observations established that R-SMADs constantly
shuttle between the cytoplasm and the nucleus [39–42]. Treat-
ment of cells with SB-431542, a relatively selective inhibitor of
the type I TGFß receptors [43], resulted in rapid dephosphorylation
of SMAD2 and redistribution from the nucleus to the cytoplasm
[40]. These observations pointed to the existence of a R-SMAD
phosphatase in the nucleus. Indeed in vitro nuclear export assays
of SMAD2 using isolated nuclei from TGFß-treated HeLa cells dem-
onstrated that only dephosphorylated SMAD2 was exported from
the nucleus [42]. More recently, a mathematical model, built using
the observations of real-time nuclear-cytoplasmic shuttling of
SMAD2 upon ligand treatment, permits for a nuclear SMAD2-tail
phosphatase [39]. Furthermore, proteasomal inhibitors such as
MG-132 only partially rescue the levels of tail-phosphorylated
SMADs upon removal of ligands or inhibition of the type I receptors
[44]. This indicates that ubiquitylation and degradation of R-
SMADs play a signiﬁcant but partial role in terminating R-SMAD
activity. Collectively these observations have formed the basis for
the search for R-SMAD phosphatases, focussing primarily on the
activating tail-phosphorylation (SXS) sites.
6. SMAD2/3-tail phosphatases in the TGFß pathway
Protein phosphatase Mg2+/Mn2+ dependent 1A (PPM1A; also
known as PP2Ca) was the ﬁrst phosphatase proposed to dephos-
phorylate the SMAD2/3-tail SXSmotif (Fig. 2) [45]. In HEK293T cells
overexpressing constitutively active rat type I TGFß receptor, Feng
and coworkers observed that overexpression of only PPM1A but
not 38 other S/TPs resulted in reduced levels of tail-phosphorylated
SMAD2/3 [45]. The ability of DUSPs or PTPs to yield any changes in
the levels of phospho-SMAD2/3 was not assayed in this study. The
dephosphorylation of type I TGFß receptors upstream of SMAD2/3
would also be predicted to lead to the reduction in levels of phos-
pho-SMAD2/3. In order to demonstrate that PPM1A acts directly
on SMAD2/3, the authors showed that PPM1A bound to SMAD2/3
and dephosphorylated phospho-SMAD2/3 in vitro. It was then dem-
onstrated that overexpression of PPM1A in cells enhanced the
TGFß-induced phosphorylation of SMAD2/3 and transcription of
TGFß-target genes. Conversely, knocking down PPM1A by shRNA re-
sulted in enhanced TGFß-induced phosphorylation of SMAD2/3 and
transcription of TGFß-target genes. The overexpression of PPM1A in
Zebraﬁsh embryos caused fusion of the eyes and thinner posterior
notochord, phenotypes consistent with an inhibition of nodal
signalling, which signals through SMAD2/3. The authors also
D.L. Bruce, G.P. Sapkota / FEBS Letters 586 (2012) 1897–1905 1901demonstrated that PPM1A was detected exclusively in the nuclear
fractions isolated from HaCaT keratinocytes, thus appearing to re-
solve the long-standing search for a nuclear SMAD2/3 phosphatase
in the TGFß pathway [45]. The nuclear localisation of PPM1A pre-
sented by the authors in this study contradicts our observations
of PPM1A localisation in at least 10 different cell lines, including
HaCaT cells, in which we ﬁnd that endogenous PPM1A is exclu-
sively cytoplasmic (unpublished ﬁndings). Nonetheless, the ideal
system to validate the role of PPM1A as a bona ﬁde SMAD2/3 phos-
phatase would be in cells derived from PPM1A knockout mice or
frommice in which the wild type PPM1A is homozygously replaced
with a catalytically inactive mutant. Cells or tissues derived from
PPM1A-null mice and corresponding wild type mice should also
help address deﬁnitively the subcellular localisation of PPM1A. In-
deed Feng and coworkers recently reported isolation of ﬁbroblasts
from PPM1A-null mice [46]. Surprisingly, the effects of PPM1A
knockout on TGFß-induced phosphorylation of SMAD2/3, gene
transcription as well as the phenotype of PPM1A-null mice were
not discussed in this report [46]. Instead it was reported that
PPM1A dephosphorylates RanBP3 and enhances its ability to export
SMAD2/3 out of the nucleus after TGFb stimulation [46]. More re-
cently, another study independently reported that PPM1A knockout
mice were viable and displayed no morphological phenotypes [47].
The report claimed that during cutaneous wound healing, the re-
epithelialization and keratinocyte migration was delayed in a
SMAD2-dependent manner in PPM1A-knockout mice compared
to the wild type. Interestingly, the report demonstrated a slight
enhancement of phospho-SMAD2 levels in wound tissues derived
from PPM1A knockout mice compared to wild type, although the
number of representative samples used was very limited [47]. A de-
tailed kinetic analysis of SMAD2/3 dephosphorylation following
TGFß stimulation in cells derived from PPM1A-null mice was lack-
ing [47]. Now that two groups have independently generated
PPM1A knockout mouse lines, we can anticipate deﬁnitive studies
to establish whether PPM1A indeed acts as a SMAD2/3 phosphatase
in the TGFß pathway. It should be noted that PPM1A, like many
other phosphatases, most likely dephosphorylates many other sub-
strates. Indeed PPM1A has been reported to dephosphorylate p38
MAPK, RanBP3, CDK2, Axin and IKKb [46,48–52]. Therefore it is
important to understand the precise molecular mechanisms of spa-
tial and temporal action of PPM1A on phospho-SMAD2/3.
In addition to PPM1A, other phosphatases have been proposed
to act as SMAD2 and or SMAD3 phosphatases. PP2A was reported
to mediate the dephosphorylation of SMAD3, but not SMAD2, only
under hypoxic conditions [53]. The study showed that PP2A asso-
ciates with SMAD3 only in hypoxia. This association affects TGFß-
induced nuclear accumulation of phospho-SMAD3 as well as the
transcription of SMAD3-dependent target genes [53]. The report
is intriguing in that one of the most promiscuous phosphatases,
PP2A, can selectively act on a speciﬁc SMAD protein (in this case
SMAD3) only under hypoxia. It also highlights an important point
that even though many phosphatases may be able to dephosphor-
ylate numerous phospho-proteins under overexpression condi-
tions or in vitro, substrate speciﬁcity in cells is most likely
deﬁned by how the phosphatase is recruited to its target. Under
normoxic conditions however, PP2A did not appear to act as a
SMAD3 phosphatase, suggesting speciﬁc factors or modiﬁcations
induced by hypoxia may mediate the interaction between SMAD3
and PP2A [53]. The role of PP2A as SMAD3 phosphatase has not yet
been evaluated in mouse models displaying abrogated PP2A activ-
ity. Recently, a study reported that myotubularin related protein 4
(MTMR4), a DUSP family member, bound to and dephosphorylated
SMAD2/3 to attenuate TGFß signalling [54]. MTMR4 was chosen
for this study as a putative SMAD2/3 phosphatase as it possessed
a FYVE domain, similar to the one present in SARA that is known
to mediate the interaction with SMAD2/3 in cells [54]. The studyshows that overexpression of MTMR4 resulted in the sequestration
of TGFß-induced phospho-SMAD3 in early endosomes thus inhib-
iting nuclear accumulation of active SMAD3 [54]. On the other
hand, knocking down MTMR4 led to sustained SMAD3 activation
[54]. However, the evidence to suggest that MTMR4 acts directly
on phosphorylated SMAD2/3 was lacking. As with other proposed
SMAD2/3 phosphatases, many questions on the mechanisms of ac-
tion and regulation of MTMR4 remain unanswered.7. SMAD1/5/8-tail phosphatases in the BMP pathway
The mode of activation and the nature of the SXS phosphoryla-
tion motif of BMP-SMADs are almost identical to the TGFß-SMADs.
However, distinct phosphatases have been proposed to catalyse
the removal of phosphates from the SXS motif of BMP-SMADs. A
mitochondrial enzyme, pyruvate dehydrogenase phosphatase
(PDP) was the ﬁrst phosphatase to be proposed as a SMAD1-tail
phosphatase (Fig. 3) [55]. PDP is a member of the PPM serine/thre-
onine phosphatase family. By employing RNA interference based
screening to deplete 44 serine/threonine phosphatases from Dro-
sophila S2 cells, PDP was identiﬁed to be essential for dephospho-
rylation of MAD, the Drosophila homologue of SMAD1. Several
biochemical assays on both Drosophila and human PDP demon-
strated that PDP could act as a SMAD1-tail phosphatase in vitro
and in cells overexpressing PDP. Furthermore, depletion of PDP
enhanced BMP/DPP responses in cells [55]. The molecular
mechanisms by which PDP recognizes and dephosphorylates
BMP-SMADs in the cells remain to be elucidated.
The discovery of PDP as a mitochondrial BMP-SMAD-phospha-
tase left the nuclear phosphatase(s) still elusive. Knockaert et al.
proposed Small C-terminal domain phosphatases (SCPs) as nuclear
BMP-SMAD tail-phosphatases (Fig. 3) [44]. In a phenotype-based
screen, Xenopus SCP2 mRNA microinjected into the ventral mar-
ginal zone of Xenopus embryos caused partial duplication of axis,
phenotype consistent with inhibition of the BMP pathway [44].
The human SCPs, (SCP1-3) were also able to induce partial duplica-
tion of axis in Xenopus embryos. The study further established that
SMAD1-tail was dephosphorylated directly by SCPs, both in vitro
and in cells. However SCPs did not dephosphorylate SMAD2/3-tail.
SCPs associated with SMAD1 with a higher afﬁnity compared to
SMAD2/3 [44]. Depletion of SCP2 from multiple human cell lines
was sufﬁcient to enhance and sustain high levels of tail-phosphor-
ylated SMAD1 following BMP-treatment. Consequently, depletion
of SCP2 also enhanced BMP transcriptional responses in cells. Fur-
thermore, a siRNA-resistant silent mutant of SCP2 was able to res-
cue the enhanced BMP-induced phospho-SMAD1 levels seen with
RNAi-mediated depletion of SCP2. It was also reported that SCP2
and tail-phosphorylated SMAD1 co-localise in the nucleus upon
BMP treatment [44]. It is still unclear precisely how the activity
of SCP2 as well as its recognition of BMP-SMADs is regulated.
SCP2-null or activity deﬁcient mouse models would be the only
deﬁnitive way to address the potential role of SCP2 in the BMP
pathway. In a proteomic approach we undertook to identify poten-
tial regulators of SCP2, we isolated over 600 proteins that associ-
ated with SCP2 (unpublished data). This indicates that SCPs may
be very promiscuous with regards to the number of proteins they
might dephosphorylate. Recently, a large proline-rich protein
BAT3 was identiﬁed as a co-factor of the phospho-tail SMAD1-
SCP2 complex [56]. BAT3 has been implicated in various signalling
networks and appears to potentiate the interaction between
SMAD1 and SCP2 after receptor phosphorylation, with the knock-
down of BAT3 increasing the expression of BMP-responsive genes
[56]. More recently, a study demonstrated that SCP1 overexpres-
sion inhibited BMP-induced osteoblastic differentiation [57].
Rather surprisingly the osteoblastic differentiation induced by
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active BMPR1 was also inhibited by SCP1 in a phosphatase activity-
dependent manner [57]. These results imply that dephosphoryla-
tion of non-SMAD targets may also contribute to the inhibition of
the BMP pathway by SCPs [57].
In addition to dephosphorylating SMAD2/3 and attenuating
TGFß signalling, PPM1A was also proposed to act as SMAD1-tail
phosphatase leading to the inhibition of BMP signalling (Fig. 3)
[58]. PPM1A overexpression resulted in the inhibition of BMP-in-
duced phospho-SMAD1 as well as the expression of BMP-target
genes, while RNAi-knockdown enhanced BMP responses [58].
While PPM1A overexpression in Zebraﬁsh embryos resulted in phe-
notypes consistent with the inhibition of nodal signalling, no ef-
fects resulting from its inhibition of the BMP signalling were
reported [58]. Furthermore the role of PPM1A on BMP-SMADs
has not yet been reported in cells derived from PPM1A-null mice
[46,47]. A recent study suggested that PPM1A inhibits BMP signal-
ling by promoting the proteasomal degradation of SMAD1 [59].
PPM1A was shown to have a negative impact on BMP signalling
even when a constitutively active form of SMAD1 was overexpres-
sed. Similarly, PPM1A overexpression led to a reduction of SMAD1
protein levels, which was blocked by Lactacystin, a proteosomal
inhibitor [59].
8. R-SMAD linker phosphatases
R-SMAD phosphorylation at the linker region is a very promi-
nent event mediated by multiple Ser/Thr protein kinases down-
stream of a variety of agonists and environmental factors (Fig. 1).
Therefore, the linker region provides an important avenue for inte-
gration of regulatory inputs from multiple signalling networks to
inﬂuence the outcome of TGFß/BMP signalling. When R-SMADs
are overexpressed in cells, they are in fact rapidly and spontane-
ously phosphorylated at the linker region, mainly on the proline-
directed Ser/Thr residues, even in the absence of ligands [60].
Two groups independently reported SCPs as prominent R-SMAD-
linker phosphatases (Figs. 2 and 3) [60,61]. In overexpression as-
says, SCP1-3 were able to efﬁciently dephosphorylate the
SMAD2-linker sites at Ser245, Ser250 and Ser255 and analogous
SMAD3 sites [60,61]. Interestingly SCPs were unable to dephos-
phorylate Thr179 of SMAD3, although most proline-directed ki-
nases that phosphorylate the SMAD2/3-linker also induce the
phosphorylation of Thr179 [61]. RNAi-mediated depletion of
SCP1-3 resulted in enhanced phosphorylation of SMAD2/3-linker
but did not affect the levels of SMAD2/3-tail phosphorylation
[60,61]. Overexpression of SCPs enhanced TGFß-induced phos-
phorylation of SMAD2 as well as TGFß-induced gene transcription
[60,61]. Conversely, RNAi-mediated depletion of SCP1/2 resulted in
the inhibition of TGFß-induced transcription of several target
genes [60,61]. This is consistent with the notion that enhanced
SMAD2/3-linker phosphorylation inhibits TGFß-responses. In addi-
tion to the SMAD2/3-linker, the linker sites in SMAD1 were also
targeted by SCP1-3 in both mammalian cells and in Xenopus em-
bryos [60]. SCP1-3 dephosphorylated SMAD1-linker sites at
Ser187, Ser195, Ser206 and Ser214 as detected by a PXS⁄P (where
S⁄ is a phospho-Ser) antibody [21,60]. As discussed earlier, SCPs
also dephosphorylated SMAD1-tail sites [21]. RNAi-depletion of
SCP1/2 resulted in the enhancement of the levels of BMP-induced
phospho-linker as well as phospho-tail SMAD1 resulting in en-
hanced transcription of BMP target genes [21,60]. The distinction
in substrate speciﬁcity displayed by SCPs towards BMP vs TGFß-
SMADs is quite intriguing. This could perhaps be explained by
the relatively higher afﬁnity SCPs have for BMP-SMADs over
TGFß-SMADs [44]. It is likely that by dephosphorylating SMAD2/
3-linker but not tail-sites, the SCPs enhance TGFß-signalling butby dephosphorylating both SMAD1-linker and tail sites, the SCPs
reset SMAD1 to the basal unphosphorylated state [44,60]. In this
review and in many reports, linker phosphorylation (and dephos-
phorylation) of R-SMADs is taken as a single entity. However it is
clear that multiple phospho-residues in the linker region are regu-
lated in different ways and follow distinct kinetics of both phos-
phorylation and dephosphorylation (Fig. 1)[11,20,21,24,28]. More
detailed studies on how each of the linker sites is phosphory-
lated/dephosphorylated may shed light into how SCPs act on indi-
vidual sites. The mechanisms by which the activity of and
substrate recognition by SCPs are regulated remain to be eluci-
dated. Furthermore, in addition to the proline-directed phospho-
Ser/Thr residues, there are other non-proline-directed phospho-
residues within the R-SMAD-linker that are phosphorylated by dif-
ferent kinases (Fig. 1). It is not known whether SCPs also dephos-
phorylate these residues.
9. R-SMAD phosphatases that target non-linker and tail
phospho-sites
As demonstrated in Fig. 1, the MH1 and the MH2 domains of the
R-SMADs are targeted for phosphorylation by several kinases in re-
sponse to several agonists. Currently we do not know whether any
of the proposed SMAD-associating phosphatases also target any of
the sites other than the SXS motif and the linker sites already dis-
cussed. In most cases, appropriate tools do not exist to probe the
phosphorylation or dephosphorylation of many of these sites.
The only site outside the linker region that SCPs are reported to
dephosphorylate is Thr8 of SMAD3, which is phosphorylated in
cells by CDKs and ERK [61].
10. Phosphatases that act on TGFß/BMP receptors also modulate
R-SMAD activity
The type I TGFb/BMP receptor kinases are themselves activated
upon phosphorylation by constitutively active type II receptor ki-
nases prior to phosphorylating and activating R-SMADs. As with
the R-SMADs, the type I receptors are regulated by dephosphoryla-
tion and degradation, both of which are critical regulatory steps for
the termination of the signalling cascade. While the degradation of
type I receptors involves various E3 ubiquitin ligases and inhibitory
SMADs 6 & 7, several phosphatases have been reported to act on
type I receptors (Figs. 2 and 3). The majority of phosphatases that
have been reported to act on the cell membrane receptors belong
to the PPP and FCP families of serine/threonine phosphatases.
PP2A, a member of the PPP family, has been reported to act on type
I type I TGFb receptors ALK5 to modulate the TGFß pathway [62].
Two distinct regulatory subunits of PP2A, the Ba and Bd, appear
to regulate the TGFß pathway in opposite ways. While the knock-
down of Ba subunit suppresses nodal signalling in Xenopus em-
bryos, the depletion of Bd enhanced the nodal signalling
responses [62]. Neither subunit was reported to direct PP2A to
dephosphorylate ALK4, 5 or 7 suggesting that these subunits may
regulate the receptor activity or stability by binding to the receptors
[62]. Another PPP family member, PP1, has been reported to func-
tion at the type I receptors to impact on TGFb signalling [63]. A
two-hybrid screen identiﬁed PP1c to interact with SARA through
the PP1c binding RVXF motif [63]. In Drosophila, the interaction
with SARA allowed PP1 to be recruited to the Decapentaplegic
(Dpp) receptor, the homolog of the BMP type I receptor. The expres-
sion of SARAmutant that was unable to interact with PP1 displayed
hyperphosphorylation of the type I receptor [63]. Furthermore, ﬂies
with a catalytically inactive PP1c background displayed increased
expression of Dpp-target genes [63]. Further studies onmammalian
models have also established the role for PP1 in type I receptor
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ported to engage SARA as well as SMAD7 and GADD34 (growth ar-
rest and DNA damage protein 34) to enhance its interaction with
the type I TGFß receptors [64]. Indeed, phosphorylation of the type
I TGFß receptor was reduced in vitrowhen PP1was in complexwith
GADD34 and Smad7. However, this does not appear to be an imme-
diate feedback loop as the association of PP1 with the receptor was
only observed after stimulation with TGFb for 16 h [64]. The depen-
dence of PP1 on SMAD7 for it to be targeted to the type I receptors
was further highlighted by another study [65]. In endothelial cells,
PP1 interacted with ALK1, in a SMAD7-dependent manner, leading
to the inhibition TGFb/BMP signalling [65]. Finally, the FCP family
member Dullard was shown to be an important player in the induc-
tion of neuralisation in Xenopus embryos. Dullard was demon-
strated to interact with the BMP type II receptor and promote its
degradation as well as the repress the phosphorylation of the
BMP type I receptor. Both processes were reported to require the
active phosphatase domain of Dullard [66].
11. Concluding remarks
Although the regulation of R-SMADs by phosphorylation has
been known for over 15 years, the ﬁrst phosphatases proposed to
dephosphorylate R-SMADs made their debut just over ﬁve years
ago [44,45,55,58,60,61]. Since then more R-SMAD phosphatases
have been proposed [53,54]. The emerging debate in the ﬁeld is:
‘which of these phosphatases are in fact true R-SMAD phospha-
tases and what are the mechanisms that deﬁne substrate speciﬁc-
ity and activity of these phosphatases?’ In order to help this debate
constructively, we have drawn up a few parameters below that we
believe any potential R-SMAD phosphatase has to meet in order to
be considered a relevant candidate:
1. The phosphatase has to interact, at least transiently, with
phospho-R-SMADs. Deﬁning the mechanisms of this interaction
may yield clues to the mechanisms of action for candidate
phosphatases.
2. The phosphatase and R-SMADs should co-localise at the site of
dephosphorylation.
3. The phosphatase should be able to dephosphorylate the
appropriate phospho-residue within R-SMADs in vitro. Often
overexpression of phosphatases is used to demonstrate that
the phosphatase is able to dephosphorylate the substrate. A
negative result under these conditions may simply mean that
the phosphatase lacks the equivalent amounts of necessary reg-
ulatory subunits to be active in cells. This is particularly true forTable 1
Overview of all the reported R-SMAD phosphatases. Using the seven parameters discussed
act as R-SMAD phosphatases. Abbreviations used: TP-tail phosphorylated; LP-linker phosph
a mere reﬂection of the claims made. For most proposed R-SMAD-phosphatases, validatio
Phosphatase Target Query – the candidate phosphatase. . .
Interacts
with the R-
SMAD?
Localises
with the
R-SMAD?
Dephosphorylates
the R-SMAD
in vitro?
Affects R
function
depletion
PDP SMAD1-
TP
Yes Yes Yes Yes
SCP1/2 SMAD1-
TP
Yes Yes Yes Yes
PPM1A SMAD1/
2/3-TP
Yes Yes Yes Yes
MTMR4 SMAD2-
TP
Yes Yes Yes Yes
PP2A SMAD3-
TP
Yes No Yes Yes
SCP1/2 SMAD1/
2/3-LP
Yes Yes Yes Yesthe PPP family of phosphatases, which are controlled by multi-
ple regulatory subunits. Even for monomeric phosphatases,
overexpression may cause non-speciﬁc dephosphorylation of
multiple targets. By their promiscuous nature, many phospha-
tases would be expected to pass this test regardless of the sub-
strates used. However it is still important to demonstrate the
in vitro activity towards R-SMADs.
4. Abrogation of the phosphatase activity in cells (e.g. by knock-
down of the phosphatase or its regulatory subunits) has to
impede the rate of R-SMAD dephosphorylation. This would
entail an extended half-life of ligand-induced phospho-R-SMAD
levels, especially following the removal of appropriate ligands
and/or inhibition of the upstream kinases after a pulse of ligand
treatment. Consistent with the sustained levels of R-SMAD-
phosphorylation, depletion of candidate phosphatase would
be expected to impact on the target gene-expression and down-
stream cellular responses. Well-established phenotypic screens
using Xenopus or Zebraﬁsh embryos may provide further biolog-
ical insights of the candidate phosphatase.
5. Restoration of wild type phosphatase, but not catalytically inac-
tive or substrate-interaction deﬁcient mutants, in cells where
the phosphatase activity is abrogated should be able to rescue
the dephosphorylation of R-SMADs. For example, if the phos-
phatase is silenced by RNA interference, then rescue experi-
ments using RNAi-resistant silent mutants of the wild type
phosphatase or catalytically inactive mutant should be per-
formed. This is extremely important in order to demonstrate
that the effects on R-SMAD-phosphorylation are due to the pre-
dicted abrogation of the candidate phosphatase activity and not
due to off-target effects.
6. The ultimate test for a R-SMAD-phosphatase is to conﬁrm ﬁnd-
ings in a transgenic mouse model in which the candidate phos-
phatase gene has been knocked out or replaced with a
catalytically inactive phosphatase. With global efforts to com-
plete the targeted disruption of every gene in the human gen-
ome already underway, we may be able to accomplish this
comprehensively within the next decade. If the transgenic mice
are embryonic lethal, cells derived from such embryos will be
sufﬁcient to verify the role of the candidate phosphatase as a
R-SMAD-phosphatase. One problem with the transgenic models
may be potential redundancy of the R-SMAD phosphatases.
However, if RNAi-knockdown of the candidate phosphatase
impacts R-SMAD phosphorylation in cells, knocking out the
phosphatase in mice should yield the same outcome.
7. Ideally any candidate R-SMAD phosphatase should be indepen-
dently veriﬁed.in the text, we have queried all the published SMAD-phosphatases for their ability to
orylated. This table is not a critical assessment of the data presented in each study but
n in transgenic mouse models and independent veriﬁcation are still missing.
Reference(s):
-SMAD
upon
?
Rescue
restores
R-SMAD
function?
Has been
conﬁrmed in
mouse models?
Has been
independently
veriﬁed?
No No No [55]
Yes No No [44]
Yes No No [45,57]
No No No [54]
Yes No No [53]
No No Yes [60,61]
1904 D.L. Bruce, G.P. Sapkota / FEBS Letters 586 (2012) 1897–1905We have used these parameters to assess each of the proposed
R-SMADs phosphatases to date (Table 1). Once established as a ro-
bust candidate R-SMAD phosphatase, it is still very important to
elucidate the molecular mechanisms by which the candidate phos-
phatase recognises and acts on the R-SMAD. This is particularly
important as most phosphatases are predicted to act on multiple
substrates.
Phosphatases acting directly on R-SMADs are not the only phos-
phatases that are likely to modulate the levels of R-SMAD-phos-
phorylation or the outcome of TGFß/BMP pathways. Clearly the
phosphatases that target the TGFß-receptor complexes have a di-
rect impact on R-SMAD phosphorylation and TGFß/BMP signalling
(Figs. 2 and 3). The same would be expected of any phosphatase
that regulates the activity of any upstream R-SMAD kinase. Fur-
thermore dephosphorylation of any number of proteins such as
SMURF1, NEDD4L, SMAD4, inhibitory SMADs, and TRIM33 that
can modulate R-SMAD activity, stability or subcellular localisation
could also impact on the outcome of TGFß/BMP signalling. Phos-
phatases that impact on the transcription of R-SMADs or miRNAs
that regulate R-SMADs indirectly could also impact R-SMAD activ-
ity. These factors have to be considered carefully when setting up
genome-wide phosphatase overexpression or knockdown screens
to identify novel R-SMAD phosphatases. Additionally some of the
proposed R-SMAD phosphatases themselves may modulate the
physiological responses to TGFß ligands by targeting other compo-
nents of the TGFß/BMP pathway [57,59].
The homeostasis of almost every cell in vertebrates is regulated
in some way by TGFß/BMP signalling. As key mediators of TGFß/
BMP signals, SMAD transcription factors are tightly regulated. A
balanced cellular response to TGFß/BMP signals depends partly
on ﬁne-tuning the activity of SMAD-transcription factors. SMAD-
phosphatases are likely to play a key role in determining the extent
and duration of TGFß/BMP responses in cells. Understanding the
regulation of SMAD-phosphatases in the TGFß/BMP signalling
pathways may provide important insights into whether such phos-
phatases are compromised in diseases that are associated with
abnormal TGFß/BMP signalling.
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